Helix BioPharma Files Q1 2026 Financial Statements, Showcasing Clinical-Stage Oncology Pipeline

Helix BioPharma Corp., a clinical-stage oncology company, announced the filing of its unaudited interim financial statements for the three-month period ended October 31, 2025. The filings, which include the financial statements, management's discussion and analysis, and certifications from the Chief Executive Officer and Chief Financial Officer, are publicly available on the company's profile at https://www.sedarplus.ca and on its corporate website.

The company's pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate designed to target CEACAM6-expressing tumors. This Tumor Defense Breaker™ has completed Phase Ib studies in non-small cell lung cancer and is engineered to increase tumor sensitivity to therapy while augmenting the effectiveness of current anti-cancer treatments. The CEACAM6-targeting foundation of L-DOS47 also supports Helix's next-generation bi-specific antibody-drug conjugates, which are currently in the discovery phase.

Beyond its lead candidate, Helix advances two pre-Investigational New Drug candidates. LEUMUNA™ is an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse. GEMCEDA™ represents a first-in-class oral gemcitabine prodrug with bioavailability comparable to intravenous administration, designed to expand treatment options for patients with advanced cancers. These developments position the company at the forefront of oncology innovation targeting some of medicine's most challenging malignancies.

The financial disclosure comes as the company continues its research and development activities across multiple therapeutic platforms. For investors and stakeholders, these interim filings provide transparency into the company's financial position during a period of ongoing clinical development. The availability of these documents on regulatory and corporate platforms ensures accessibility for those monitoring the company's progress.

Helix BioPharma trades on multiple exchanges including TSX under symbol HBP, OTC PINK as HBPCD, and FWB as HBP0. The company's corporate information and additional resources can be accessed through its website at https://www.helixbiopharma.com. The recent filings represent standard regulatory compliance while the company advances its mission to develop near-term solutions for hard-to-treat cancers through innovative therapeutic approaches.